季也蒙念珠菌真菌血症:参考实验室与三级医疗中心12年抗真菌药敏回顾分析
该研究回顾了2012-2023年某参考实验室112株血培养季也蒙念珠菌的药敏数据,并对21例真菌血症患者进行临床回顾。9.8-20.5%的菌株对多种三唑类为非野生型,所有菌株对米卡芬净敏感;
要点
- 季也蒙念珠菌对多种三唑类存在非野生型(9.8-20.5%),所有分离株对米卡芬净敏感。
- 该真菌血症多为医院获得性(76.2%),且常发生于免疫受损患者(三分之二)。
- 药敏结果回报前可经验性选用棘白菌素,三唑类临床折点尚需进一步研究。
核心结论
- 季也蒙念珠菌血分离株中相当比例对多种三唑类为非野生型,但全部对米卡芬净敏感。
- 该真菌血症在免疫受损患者中死亡率高,但仅19.0%的死亡直接或部分归因于该感染。
- 在药敏结果可用前,棘白菌素可作为经验性治疗选择。
研究设计与样本
- 对2012-2023年提交至参考实验室的112株血培养季也蒙念珠菌分离株进行抗真菌药敏试验回顾分析。
- 采用CLSI和EUCAST的流行病学折点(ECV)及折点判读药敏模式。
- 对在本机构治疗的21例真菌血症患者进行回顾性病历复习,描述危险因素、治疗与结局。
主要发现
- 112株血培养分离株中,9.8-20.5%对多种三唑类为非野生型。
- 所有分离株对米卡芬净敏感。
- 21例真菌血症患者中76.2%为医院获得性,三分之二在诊断时免疫受损。
关键数值与推荐
- 药敏判读采用CLSI和EUCAST的流行病学折点(ECV)及折点。
- 非野生型三唑类比例范围为9.8-20.5%。
- 所有分离株对米卡芬净敏感。
- 76.2%的病例为医院获得性,三分之二患者免疫受损。
临床怎么用
- 在药敏结果回报前,可经验性使用棘白菌素(如米卡芬净)治疗疑似季也蒙念珠菌真菌血症。
- 对免疫受损患者的季也蒙念珠菌真菌血症应警惕高死亡率,优化治疗策略。
- 三唑类治疗需参考药敏结果,因相当比例菌株为非野生型。
局限性
- 临床数据仅来自单中心21例患者,样本量有限。
- 为回顾性研究,可能存在选择偏倚和信息偏倚。
- 三唑类临床折点尚未确定,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: The prevalence of invasive candidiasis caused by non-albicans Candida species is increasing. Candida guilliermondii is an infrequent cause of candidemia but has been associated with decreased susceptibility to triazoles. Clinical data related to the infection with C. guilliermondii are sparse. Our study evaluated the antifungal susceptibility testing (AST) for C. guilliermondii isolates submitted to a reference laboratory over a 12-year period (2012-2023). AST patterns were examined using Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) epidemiological cutoff values (ECVs) and breakpoints. Where isolates were identified from patients treated at our institution, retrospective chart review was performed to describe patient risk factors, treatment approaches, and outcomes associated with C. guilliermondii fungemia. One hundred twelve blood culture isolates of C. guilliermondii were identified, and clinical data were available for 21 fungemic patients. A significant number of isolates (9.8-20.5%) were observed to be non-wild type for various triazoles. All isolates were susceptible to micafungin. A majority (76.2%) of cases of C. guilliermondii fungemia treated at our tertiary care center were hospital-acquired, and two-thirds of patients were immunocompromised at the time of diagnosis. Ten of the 21 patients died within 60 days of fungemia, although mortality was directly or partially attributed to C. guilliermondii fungemia in only four cases (19.0%). Echinocandins may be used for empiric therapy for C. guilliermondii until the results of AST are available. Further research is required to determine appropriate clinical breakpoints for triazoles. IMPORTANCE: Our study addresses a significant knowledge gap in the clinical management of this non-Candida albicans species. Our retrospective review includes comprehensive AST data for 112 Candida guilliermondii isolates, which is the largest number of isolates reported from the United States to date. Susceptibility data are supplemented by clinical outcomes, where isolates were identified for patients treated at Mayo Clinic. Key findings from our study include the observation that a notable proportion of C. guilliermondii isolates exhibit non-wild-type profiles for various triazoles. Importantly, all isolates remained susceptible to echinocandins, suggesting their efficacy as first-line therapy in the absence of timely susceptibility results. Furthermore, our study highlights the high mortality associated with C. guilliermondii fungemia in immunocompromised patients, emphasizing the urgent need for optimized treatment strategies.
引用
- McHugh JW, Bayless DR, Ranganath N, et al. Candida guilliermondii fungemia: a 12-year retrospective review of antimicrobial susceptibility patterns at a reference laboratory and tertiary care center. J Clin Microbiol. 2024. PMID: 39440933. doi:10.1128/jcm.01057-24
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。